Earnings call Novartis delivered a resilient Q1 2026, with growth drivers up 34% YoY in constant currency, offsetting U.S. generic erosion that led to a 5% sales decline and 14% drop in core operating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results